Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F PASQUIER

Showing results (171-180 of 191) with videos related to

Pageof 20
Sort By:
Experimental Neurology|December 17, 2009
An unbiased, staged, multicentre, validation strategy for Alzheimer's disease CSF tau levelsA Petzold, M D Chapman, S Schraen, et al.
Diabetes & Metabolism|June 19, 2016
Relationship between achieved personalized glycaemic targets and monitoring of clinical events in elderly diabetic patientsS Bucher, H Panjo, A Al-Salameh, et al.
Molecular Psychiatry|September 26, 2007
Evidence for induction of the ornithine transcarbamylase expression in Alzheimer's diseaseF Bensemain, D Hot, S Ferreira, et al.
Journal of Medical Genetics|June 17, 2003
Association of 3'-UTR polymorphisms of the oxidised LDL receptor 1 (OLR1) gene with Alzheimer's diseaseJ-C Lambert, E Luedecking-Zimmer, S Merrot, et al.
The Journal of Nutrition, Health & Aging|June 19, 2009
Mild Alzheimer's disease: a "position paper"J Delrieu, T Voisin, S Andrieu, et al.
Revue Neurologique|June 12, 2024
The pattern of cortical thickness associated with executive dysfunction in MCI and SCC: The MEMENTO cohortD Andriuta, M Roussel, G Chene, et al.
American Journal of Human Genetics|February 1, 1997
Apolipoprotein E and Alzheimer disease: genotype-specific risks by age and sexH Bickeböller, D Campion, A Brice, et al.
Leukemia|September 13, 2014
Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocytemia: relevance for disease evolutionX Cabagnols, J P Defour, V Ugo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 9, 2021
Therapy-related myeloid neoplasms following treatment with PARP inhibitors: new molecular insightsJ E Martin, S Khalife-Hachem, T Grinda, et al.
Leukemia & Lymphoma|October 12, 2020
Effects of azacitidine in 93 patients with <i>IDH1/2</i> mutated acute myeloid leukemia/myelodysplastic syndromes: a French retrospective multicenter studyC Willekens, R Rahme, M Duchmann, et al.
Pageof 20

Showing results (171-180 of 191) with videos related to

Sort By:
Pageof 20
Experimental Neurology|December 17, 2009
An unbiased, staged, multicentre, validation strategy for Alzheimer's disease CSF tau levelsA Petzold, M D Chapman, S Schraen, et al.
Diabetes & Metabolism|June 19, 2016
Relationship between achieved personalized glycaemic targets and monitoring of clinical events in elderly diabetic patientsS Bucher, H Panjo, A Al-Salameh, et al.
Molecular Psychiatry|September 26, 2007
Evidence for induction of the ornithine transcarbamylase expression in Alzheimer's diseaseF Bensemain, D Hot, S Ferreira, et al.
Journal of Medical Genetics|June 17, 2003
Association of 3'-UTR polymorphisms of the oxidised LDL receptor 1 (OLR1) gene with Alzheimer's diseaseJ-C Lambert, E Luedecking-Zimmer, S Merrot, et al.
The Journal of Nutrition, Health & Aging|June 19, 2009
Mild Alzheimer's disease: a "position paper"J Delrieu, T Voisin, S Andrieu, et al.
Revue Neurologique|June 12, 2024
The pattern of cortical thickness associated with executive dysfunction in MCI and SCC: The MEMENTO cohortD Andriuta, M Roussel, G Chene, et al.
American Journal of Human Genetics|February 1, 1997
Apolipoprotein E and Alzheimer disease: genotype-specific risks by age and sexH Bickeböller, D Campion, A Brice, et al.
Leukemia|September 13, 2014
Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocytemia: relevance for disease evolutionX Cabagnols, J P Defour, V Ugo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 9, 2021
Therapy-related myeloid neoplasms following treatment with PARP inhibitors: new molecular insightsJ E Martin, S Khalife-Hachem, T Grinda, et al.
Leukemia & Lymphoma|October 12, 2020
Effects of azacitidine in 93 patients with <i>IDH1/2</i> mutated acute myeloid leukemia/myelodysplastic syndromes: a French retrospective multicenter studyC Willekens, R Rahme, M Duchmann, et al.
Pageof 20